The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.
Investors were looking for a greater difference between Ocular’s experimental medicine and a low-dose version of Eylea, ...
As the CGT market evolves, developers must answer one key question that will shape their manufacturing strategy: “Should we go with a modular platform or a fully integrated system?” Both approaches ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results